Chicken-Derived CD20 Antibodies for Stronger B Cell Depletion

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current anti-hCD20 monoclonal antibodies (mAbs) derived from mouse immunization are limited by high sequence homology with humans, leading to partial efficacy and frequent recurrence of diseases, necessitating the development of antibodies with enhanced B cell depletion activity.

Innovation Solution

Utilizing chickens as a host for immunization to generate novel anti-hCD20 mAbs that bind divergent epitopes, exhibiting improved B cell depletion activity through enhanced antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If mouse immunization is used to generate anti-hCD20 mAbs, then the antibodies can be produced, but the high sequence homology (67%) between mouse and human CD20 limits the discovery of antibodies with new specificities and enhanced therapeutic potential

Engineering Contradiction:

Improveantibody specificity diversityVSAvoidtherapeutic efficacy

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent inverts the conventional approach by using a phylogenetically distant species (chicken) instead of a closely related species (mouse) for immunization. This inversion allows the generation of antibodies with completely new specificities that do not overlap with existing anti-hCD20 antibodies, thereby resolving the limitation of high sequence homology and enabling discovery of novel therapeutic candidates.

Inventive Principle:

Principle #13The other way round (Inversion)

2Productivity

If current anti-hCD20 Abs are used, then treatment can be initiated, but the antibodies remain only partially effective and require extended treatment or combination with chemotherapy

Engineering Contradiction:

ImproveB cell depletion efficiencyVSAvoidtreatment duration

Core Design Contradiction:

ProductivityVSLoss of time

Solution Approach 1:

The patent changes the key parameter of antibody origin from mouse-derived to chicken-derived, which fundamentally alters the epitope recognition profile. This parameter change results in antibodies with enhanced ADCC and CDC potency, achieving superior B cell depletion efficiency without requiring extended treatment durations or combination therapies.

Inventive Principle:

Principle #35Parameter changes

3Reliability

If current anti-hCD20 Abs are used, then initial treatment can be provided, but 50% of patients fail to show any response and patients develop recurrent disease refractory to retreatment

Engineering Contradiction:

Improvetherapeutic response rateVSAvoidepitope binding diversity

Core Design Contradiction:

ReliabilityVSAdaptability or versatility

Solution Approach 1:

By inverting the immunization strategy to use chicken hosts, the patent generates antibodies that bind to entirely different epitopes on hCD20 compared to existing mouse-derived antibodies. This epitope diversity enables the antibodies to effectively target B cells that may have escaped or developed resistance to current therapies, thereby improving the response rate and reducing recurrence.

Inventive Principle:

Principle #13The other way round (Inversion)

Data Source

PatentUS20260055202A1Chicken-derived CD20 antibodies with potent b cell depletion activity

Publication Date: 2026.02.26 TEXAS A&M UNIVERSITY

AI summary

The present disclosure provides multiple anti-hCD20 mAbs as well as humanization of antibodies. The antibodies described herein are chicken-derived and exhibit significantly enhanced B-cell-specific antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) potency as well as improved depletion of B lymphoma cells in vivo relative to Rituximab.